Cogent Biosciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Cogent Biosciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.952.622.477.870.009.73
Cost of Revenue0.000.000.000.00-46.910.000.00
Gross Profit0.000.952.622.4754.780.000.00
Operating Expenses
Research & Development232.66173.76121.6355.9125.7443.7138.29
Selling, General & Administrative43.2834.3826.2119.6417.4210.977.45
Operating Expenses275.94208.13147.8475.5543.1654.6845.74
Operating Income-275.94-208.13-147.84-75.55-82.20-54.68-36.01
Other Income/Expense
Interest Income18.0913.083.990.470.140.001.15
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense20.08-0.943.612.81-7.25-22.580.32
Income
Income Before Tax-255.86-194.11-140.24-72.2719.01-31.83-34.53
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-255.86-192.41-140.24-72.27-74.81-31.83-34.53
Net Income - Continuous Operations-255.86-192.41-140.24-72.270.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-271.59-188.82-141.96-75.40-34.57-30.59-34.68
EBIT-255.86-192.41-147.84-75.55-35.29-31.83-36.01
Depreciation & Amortization4.352.305.880.150.70-1.290.00
Earnings Per Share
Basic EPS-2.00-2.00-2.00-2.00-16.00--6.00
Diluted EPS-2.00-2.00-2.00-2.00-16.00-4.00-6.00
Basic Shares Outstanding103.8679.6658.7438.7311.087.626.22
Diluted Shares Outstanding103.8679.6658.7438.7311.087.626.22